Gastroduodenitis Associated with Active Ulcerative Colitis Treated with Infliximab: Different Clinical Course in the Colon and Gastroduodenal Lesions
-
- Hayashi Tomoyuki
- Department of Gastroenterology, Kanazawa University Hospital, Japan
-
- Terashima Takeshi
- Department of Gastroenterology, Kanazawa University Hospital, Japan
-
- Nishitani Masaki
- Department of Gastroenterology, Kanazawa University Hospital, Japan
-
- Orita Noriaki
- Department of Gastroenterology, Kanazawa University Hospital, Japan
-
- Miyazawa Masaki
- Department of Gastroenterology, Kanazawa University Hospital, Japan
-
- Seki Akihiro
- Department of Gastroenterology, Kanazawa University Hospital, Japan
-
- Nakagawa Hidetoshi
- Department of Gastroenterology, Kanazawa University Hospital, Japan
-
- Nio Kouki
- Department of Gastroenterology, Kanazawa University Hospital, Japan
-
- Iida Noriho
- Department of Gastroenterology, Kanazawa University Hospital, Japan
-
- Yamada Shinya
- Endoscopy Center, Kanazawa University Hospital, Japan
-
- Takatori Hajime
- Endoscopy Center, Kanazawa University Hospital, Japan
-
- Shimakami Tetsuro
- Department of Gastroenterology, Kanazawa University Hospital, Japan
-
- Yamashita Taro
- Department of Gastroenterology, Kanazawa University Hospital, Japan
抄録
<p>A 29-year-old man with severe ulcerative colitis and gastroduodenitis was initially treated with oral mesalamine and high-dose intravenous steroid therapy; however, his epigastralgia and vomiting did not improve. After initiating infliximab, the patient experienced prompt improvement in symptoms and inflammation. Although steroids were effective for the colon, they proved ineffective for gastroduodenal lesions, highlighting the necessity for molecular-targeted agents, such as infliximab, in these cases. The timing for administering such agents should be carefully considered. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 63 (7), 929-935, 2024-04-01
一般社団法人 日本内科学会